PTC Therapeutics
Translarna (ataluren), a small-molecule therapeutic that enables read-through of nonsense mutations in dystrophin gene for Duchenne muscular dystrophy
- Sector
- Biotech
- Latest Form D
- $35.9M, May 2023
- Total capital
- $502M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $483M
- 10 Form D · last May 2023
- 42 months since last filing
- Federal contracts
- $18.6M
- 1 award · Defense
- Rank in Biotech#45 of 4373
- Granted patents
- 0
- 19 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 10th filing$35.9M
- Private capital raisedForm D · SEC · 9th filing$41.9M
- Private capital raisedForm D · SEC · 8th filing$141M
- Private capital raisedForm D · SEC · 7th filing$150M
- Private capital raisedForm D · SEC · 6th filing$4.5M
- Private capital raisedForm D · SEC · 5th filing$60M
- Private capital raisedForm D · SEC · 4th filing$2M
- Private capital raisedForm D · SEC · 3rd filing$23M
- Private capital raisedForm D · SEC · 2nd filing$25.2M
- Offering registeredForm D · SEC · 1st filing$1M
Show 1 earlier federal award
- Federal contractDefense · Program Funding$18.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
36months
from PTC Therapeutics’s first federal award to its first private round.
- First federal award · Sep 2006
- Defense · $18.6M
- First Form D · Oct 2009
- $1M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Founders and team
From SEC Form D filings- Adam P. KoppelDirectorNamed in SEC Form D filings
- Alethia YoungDirectorNamed in SEC Form D filings
- Allan S. JacobsonDirectorNamed in SEC Form D filings
- Allan Jacobson, Ph.D.DirectorNamed in SEC Form D filings
- Axel P. BolteDirectorNamed in SEC Form D filings
- Carl P. GoldfischerDirectorNamed in SEC Form D filings
Show all 43 people
- Christine S. UtterExecutive OfficerNamed in SEC Form D filings
- Claudia W. HirawatExecutive OfficerNamed in SEC Form D filings
- David P. SouthwellDirectorNamed in SEC Form D filings
- David P. SouthwellDirectorNamed in SEC Form D filings
- Dawn D. SvoronosDirectorNamed in SEC Form D filings
- Deepa P. PakianathanDirectorNamed in SEC Form D filings
- Emily S. HillExecutive OfficerNamed in SEC Form D filings
- Emma S. ReeveDirectorNamed in SEC Form D filings
- Eric B. PauwelsExecutive OfficerNamed in SEC Form D filings
- Geoffrey P. McDonoughDirectorNamed in SEC Form D filings
- Glenn D. Steele Jr., M.D., Ph.D.DirectorNamed in SEC Form D filings
- Glenn D. Steele, Jr.DirectorNamed in SEC Form D filings
- Glenn D. Steele Jr., M.D., Ph.D.DirectorNamed in SEC Form D filings
- Jerome B. Zeldis, M.D., Ph.D.DirectorNamed in SEC Form D filings
- Jerome B. ZeldisDirectorNamed in SEC Form D filings
- Jerome B. Zeldis, M.D., Ph.D.DirectorNamed in SEC Form D filings
- Langdon L. MillerExecutive OfficerNamed in SEC Form D filings
- Langon L. MillerExecutive OfficerNamed in SEC Form D filings
- Marcio S. SouzaExecutive OfficerNamed in SEC Form D filings
- Mark E. BouldingExecutive OfficerNamed in SEC Form D filings
- Mark E. BouldingExecutive OfficerNamed in SEC Form D filings
- Mary SmithDirectorNamed in SEC Form D filings
- Matthew B. Klein, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Matthew B. KleinExecutive OfficerNamed in SEC Form D filings
- Matthew B. Klein, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Michael P. KrandaDirectorNamed in SEC Form D filings
- Michael S. SchmertzlerDirectorNamed in SEC Form D filings
- Neil W. AlmsteadExecutive OfficerNamed in SEC Form D filings
- Neil Almstead, Ph.DExecutive OfficerNamed in SEC Form D filings
- Peter P. SvennilsonDirectorNamed in SEC Form D filings
- Richard B. AldrichDirectorNamed in SEC Form D filings
- Soren P. CarlsenDirectorNamed in SEC Form D filings
- Stepanie S. OkeyDirectorNamed in SEC Form D filings
- Stepanie S. OkeyDirectorNamed in SEC Form D filings
- Stephanie S. OkeyDirectorNamed in SEC Form D filings
- Stuart W. PeltzExecutive Officer, DirectorNamed in SEC Form D filings
- William E. Baird, IIIExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 19- PendingGranules For SuspensionUSPTOApplication 19110609
- PendingHeterocyclic And Heteroaryl Compounds For Treating Huntington's DiseaseUSPTOApplication 19344653
- PendingCompounds For Treating Spinal Muscular AtrophyUSPTOApplication 19314712
Show all 19 patent records
- Granules For SuspensionApr 2, 2026 · Application 19110609Pending
- Heterocyclic And Heteroaryl Compounds For Treating Huntington's DiseaseJan 29, 2026 · Application 19344653Pending
- Compounds For Treating Spinal Muscular AtrophyJan 8, 2026 · Application 19314712Pending
- Compounds For Treating Spinocerebellar Ataxia Type 3Dec 18, 2025 · Application 18877505Pending
- Heterocyclic And Heteroaryl Compounds For Treating Huntington's DiseaseNov 20, 2025 · Application 18871302Pending
- Carboline Compounds And Use ThereofJun 12, 2025 · Application 18725509Pending
- Inhibitors Of NLRP3Jun 5, 2025 · Application 18839229Pending
- Pharmaceutical Composition Of SepiapterinFeb 6, 2025 · Application 18696567Pending
- Novel Rna TranscriptDec 12, 2024 · Application 18586114Pending
- Methods For Treating Neurogenerative DiseasesNov 28, 2024 · Application 18689761Pending
- Methods For Treating Neurogenerative DiseasesNov 21, 2024 · Application 18689624Pending
- Methods For Treating Neurogenerative DiseasesNov 14, 2024 · Application 18689680Pending
- Heteroaryl Compounds For Treating Huntington's DiseaseOct 10, 2024 · Application 18293349Pending
- Carboline Compounds And Use ThereofApplication PCTUS2024029695Pending
- Method Of Electrolytic Oxidative Cleavage Of Trolox AmideApplication PCTUS2024057928Pending
- Treatment Of Huntingtons DiseaseApplication PCTUS2025033168Pending
- Treatment Of Huntingtons DiseaseApplication 63661890Pending
- Methods For Increasing Vatiquinone Plasma ExposureApplication PCTUS2024033847Pending
- Formulations For Stabilizing Dissolution Of MedicamentsApplication PCTUS2025019817Pending
Related companies, and why
- Oxford Nanopore TechnologiesSimilar federal contract value in Biotech · $19.9M in contracts
- Rxbio, Inc.Similar federal contract value in Biotech · $18.8M in contracts
- Arteriocyte, Inc.Similar federal contract value in Biotech · $18.7M in contracts
- TALPHERA, INC.Similar federal contract value in Biotech · $17M in contracts
- BIOPROTECTION SYSTEMS CORPORATIONSimilar federal contract value in Biotech · $15.9M in contracts
- REPLIGEN CORPSimilar federal contract value in Biotech · $14.9M in contracts
Press
PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry marketFierceBiotech
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .